For women over 40, combined hormonal contraception (COCP) can be beneficial in reducing menstrual bleeding and pain, as well as alleviating menopausal symptoms. However, it is important to consider certain factors when prescribing COCP to women over 40. The UKMEC criteria for women over 40 is 2, while for women from menarche until 40, it is 1. The Faculty of Sexual and Reproductive Health recommends the use of COCP until age 50, provided there are no other contraindications. However, women over 50 should be advised to switch to a safer alternative method of contraception, as the risks associated with COCP use outweigh the benefits. Women who smoke should stop using COCP at 35, as smoking increases the risk of mortality. While COCP is associated with a reduced risk of ovarian and endometrial cancer, there is a slightly increased risk of breast cancer among women using COCP, which diminishes after 10 years of cessation. Women using COCP for non-contraceptive benefits after the age of 50 should be considered on an individual basis using clinical judgement and informed choice.

Women over the age of 40 still require effective contraception until they reach menopause, despite a significant decline in fertility. The Faculty of Sexual and Reproductive Healthcare (FSRH) has produced specific guidance for this age group, titled Contraception for Women Aged Over 40 Years. No method of contraception is contraindicated by age alone, with all methods being UKMEC1 except for the combined oral contraceptive pill (UKMEC2 for women >= 40 years) and Depo-Provera (UKMEC2 for women > 45 years). The FSRH guidance provides specific considerations for each method, such as the use of COCP in the perimenopausal period to maintain bone mineral density and reduce menopausal symptoms. Depo-Provera use is associated with a small loss in bone mineral density, which is usually recovered after discontinuation. The FSRH also provides a table detailing how different methods may be stopped based on age and amenorrhea status. Hormone replacement therapy cannot be relied upon for contraception, and a separate method is needed. The FSRH advises that the POP may be used in conjunction with HRT as long as the HRT has a progestogen component, while the IUS is licensed to provide the progestogen component of HRT.

For women, the appropriate location to take swabs for chlamydia and gonorrhoea is the vulvo-vaginal area, specifically the introitus.

Chlamydia is the most common sexually transmitted infection in the UK caused by Chlamydia trachomatis. It is often asymptomatic but can cause cervicitis and dysuria in women and urethral discharge and dysuria in men. Complications include epididymitis, pelvic inflammatory disease, and infertility. Testing is done through nuclear acid amplification tests (NAATs) on urine or swab samples. Screening is recommended for sexually active individuals aged 15-24 years. Doxycycline is the first-line treatment, but azithromycin may be used if contraindicated. Partners should be notified and treated.

Cervical Screening Guidelines in the UK

Cervical screening is an important aspect of women’s health in the UK. The age range for screening varies between 25-64 in England and Wales, and 20-60 in Scotland. The screening interval also varies depending on the country. It is important to note that a patient who is too young or has had a normal smear test within the recommended time frame is not overdue for screening.

According to the latest guidance, women who are taking maintenance immunosuppression medication post-transplantation should follow the national guidelines for non-immunosuppressed individuals. This also applies to other special circumstances, such as HIV-positive patients, who should follow the same age range for screening as the general population.

It is important to note that being homosexual and never having had a male partner doesn’t exempt a woman from screening. Women can still be exposed to HPV through a female partner who may have had previous male partners. Therefore, all women with a cervix should be considered as screening candidates and encouraged to attend.

As per the current NICE CKS guidance, it is recommended to continue iron replacement for 3 months after correcting iron deficiency anaemia, and then discontinue it.

However, in the case of this patient, it is too early to stop the iron tablets as it takes at least 3 months for iron stores to replenish. Once the replacement is adequate, prophylactic iron is not necessary as the patient’s menorrhagia has resolved.

It is important to check haemoglobin levels 2-4 weeks after starting iron tablets, and a rise of approximately 2 g/100 mL over 3-4 weeks is expected. If there is insufficient improvement despite adherence to treatment, specialist referral should be considered. In this patient’s case, the haemoglobin levels have risen adequately, and there is no need for referral.

Iron deficiency anaemia is a prevalent condition worldwide, with preschool-age children being the most affected. The lack of iron in the body leads to a decrease in red blood cells and haemoglobin, resulting in anaemia. The primary causes of iron deficiency anaemia are excessive blood loss, inadequate dietary intake, poor intestinal absorption, and increased iron requirements. Menorrhagia is the most common cause of blood loss in pre-menopausal women, while gastrointestinal bleeding is the most common cause in men and postmenopausal women. Vegans and vegetarians are more likely to develop iron deficiency anaemia due to the lack of meat in their diet. Coeliac disease and other conditions affecting the small intestine can prevent sufficient iron absorption. Children and pregnant women have increased iron demands, and the latter may experience dilution due to an increase in plasma volume.

The symptoms of iron deficiency anaemia include fatigue, shortness of breath on exertion, palpitations, pallor, nail changes, hair loss, atrophic glossitis, post-cricoid webs, and angular stomatitis. To diagnose iron deficiency anaemia, a full blood count, serum ferritin, total iron-binding capacity, transferrin, and blood film tests are performed. Endoscopy may be necessary to rule out malignancy, especially in males and postmenopausal females with unexplained iron-deficiency anaemia.

The management of iron deficiency anaemia involves identifying and treating the underlying cause. Oral ferrous sulfate is commonly prescribed, and patients should continue taking iron supplements for three months after the iron deficiency has been corrected to replenish iron stores. Iron-rich foods such as dark-green leafy vegetables, meat, and iron-fortified bread can also help. It is crucial to exclude malignancy by taking an adequate history and appropriate investigations if warranted.

A woman under 30 years old who presents with an unexplained breast lump, with or without pain, may not meet the 2-week-wait referral criteria but can still be referred for further evaluation. The most likely diagnosis is a fibroadenoma, which is a common benign breast lump that often occurs in younger women. These lumps are typically firm, smooth, and highly mobile, and can be described as a breast mouse due to their tendency to move away from the examiner’s hand. While a referral to a breast clinic is necessary, routine referral is appropriate given the low likelihood of cancer. There is no need to arrange mammograms or ultrasounds as these will be done by the breast clinic. Reviewing the patient in one month is unnecessary as the lump has persisted for two months and is not cyclical. Urgent referral to a breast clinic is not necessary given the patient’s age and low likelihood of breast cancer. According to NICE CKS, a 2-week-wait referral is recommended for those over 30 years old with an unexplained breast lump, or over 50 years old with unilateral nipple changes. Consideration of a 2-week-wait referral is also recommended for those over 30 years old with an unexplained lump in the axilla or skin changes suggestive of breast cancer.

In 2015, NICE released guidelines for referring individuals suspected of having breast cancer. If a person is 30 years or older and has an unexplained breast lump with or without pain, they should be referred using a suspected cancer pathway referral for an appointment within two weeks. Similarly, if a person is 50 years or older and experiences discharge, retraction, or other concerning changes in one nipple only, they should also be referred using this pathway. If a person has skin changes that suggest breast cancer or is 30 years or older with an unexplained lump in the axilla, a suspected cancer pathway referral should be considered for an appointment within two weeks. For individuals under 30 years old with an unexplained breast lump with or without pain, a non-urgent referral should be considered.

Marsupialisation is the definitive treatment for Bartholin’s abscess, which presents with sudden pain and difficulty urinating. On examination, a hard mass with surrounding cellulitis is found at the site of the Bartholin’s glands in the vulvar vestibule. The abscess is caused by infection of the Bartholin’s cyst. Bartholin’s cyst, on the other hand, is caused by a buildup of mucous secretions from the Bartholin’s glands and is typically asymptomatic unless it grows larger. Inclusion cysts, which are caused by vaginal wall trauma, are usually small and found on the posterior vaginal wall. Skene’s gland cysts, which form when the duct is obstructed, may cause dyspareunia or urinary tract infection symptoms. Vesicovaginal fistulas, which allow urine to continuously discharge into the vaginal tract, require surgical treatment.

Understanding Bartholin’s Abscess

Bartholin’s glands are two small glands situated near the opening of the vagina. They are typically the size of a pea, but they can become infected and swell, resulting in a Bartholin’s abscess. This condition can be treated in a variety of ways, including antibiotics, the insertion of a word catheter, or a surgical procedure called marsupialization.

Treatment options for hypoactive sexual desire disorder in women

Hypoactive sexual desire disorder is a common issue among postmenopausal women and those who have undergone ovarian failure. While counselling and lifestyle changes may be effective in cases where the primary cause is stress or relationship issues, they may not be enough in cases where hormonal imbalances are the root cause.

If depression is the primary cause, it may need to be treated, but some antidepressants can actually worsen the problem by reducing libido. In cases where hormones are inadequate, hormone replacement therapy (HRT) may be necessary, but caution should be exercised, and an opinion from a specialist may be wise.

Androgen patches are sometimes used to treat hormone-deficient women, but their effectiveness is controversial, and they may have negative effects on the liver and cholesterol. Progestogens are not necessary for women who have had a hysterectomy and may actually make symptoms worse. Overall, treatment options for hypoactive sexual desire disorder should be tailored to the individual and their specific needs.

Endometrial cancer is associated with obesity, while cervical cancer is not.

Understanding Cervical Cancer and its Risk Factors

Cervical cancer is a type of cancer that affects the cervix, which is the lower part of the uterus. It is most commonly diagnosed in women under the age of 45, with the highest incidence rates occurring in those aged 25-29. The cancer can be divided into two types: squamous cell cancer and adenocarcinoma. Symptoms of cervical cancer may include abnormal vaginal bleeding, such as postcoital, intermenstrual, or postmenopausal bleeding, as well as vaginal discharge.

The most significant risk factor for cervical cancer is infection with the human papillomavirus (HPV), particularly serotypes 16, 18, and 33. Other risk factors include smoking, human immunodeficiency virus (HIV), early first intercourse, many sexual partners, high parity, and lower socioeconomic status. The mechanism by which HPV causes cervical cancer involves the production of oncogenes E6 and E7 by HPV 16 and 18, respectively. E6 inhibits the p53 tumour suppressor gene, while E7 inhibits the RB suppressor gene.

While the strength of the association between combined oral contraceptive pill use and cervical cancer is sometimes debated, a large study published in the Lancet in 2007 confirmed the link. It is important for women to undergo routine cervical cancer screening to detect any abnormalities early on and to discuss any potential risk factors with their healthcare provider.

Surgical Referral for Faecal and Urinary Incontinence

NICE guidelines recommend surgical referral for patients with faecal incontinence. Female patients with urinary incontinence should be referred to a urological expert with specific training and experience in treating stress incontinence. Surgical techniques for stress incontinence include mid-urethral tape and mesh suspension procedures, slings, intramural bulking agents, and traditional repair techniques. Other reasons for surgical referral include persistent bladder or urethral pain, pelvic masses, neurological disease, previous pelvic cancer surgery, and previous pelvic irradiation. It is important for healthcare professionals to be aware of these guidelines and refer patients appropriately for surgical intervention.

When starting the combined oral contraceptive pill, it is important to inform women that there is a slight increase in the risk of breast and cervical cancer. However, it is also important to note that the pill is protective against ovarian and endometrial cancer.

Pros and Cons of the Combined Oral Contraceptive Pill

The combined oral contraceptive pill is a highly effective method of birth control with a failure rate of less than one per 100 woman years. It is a convenient option that doesn’t interfere with sexual activity and its contraceptive effects are reversible upon stopping. Additionally, it can make periods regular, lighter, and less painful, and may reduce the risk of ovarian, endometrial, and colorectal cancer. It may also protect against pelvic inflammatory disease, ovarian cysts, benign breast disease, and acne vulgaris.

However, there are also some disadvantages to consider. One of the main drawbacks is that people may forget to take it, which can reduce its effectiveness. It also offers no protection against sexually transmitted infections, so additional precautions may be necessary. There is an increased risk of venous thromboembolic disease, breast and cervical cancer, stroke, and ischaemic heart disease, especially in smokers. Temporary side effects such as headache, nausea, and breast tenderness may also be experienced.

Despite some reports of weight gain, a Cochrane review did not find a causal relationship between the combined oral contraceptive pill and weight gain. Overall, the combined oral contraceptive pill can be a safe and effective option for birth control, but it is important to weigh the pros and cons and discuss any concerns with a healthcare provider.

The UKMEC provides guidance for healthcare providers when selecting appropriate contraceptives based on a patient’s medical history. For women with an undiagnosed breast mass, starting the combined hormonal contraceptive pill is considered UKMEC 3, while continuing its use is classified as UKMEC 2. It is important to note that hormonal contraceptives may impact the prognosis of women with current or past breast cancer, which is classified as UKMEC 4 and UKMEC 3, respectively. Women with benign breast conditions or a family history of breast cancer are classified as UKMEC 1.

The choice of contraceptive for women may be affected by comorbidities. The FSRH provides UKMEC recommendations for different conditions. Smoking increases the risk of cardiovascular disease, and the COCP is recommended as UKMEC 2 for women under 35 and UKMEC 3 for those over 35 who smoke less than 15 cigarettes/day, but is UKMEC 4 for those who smoke more. Obesity increases the risk of venous thromboembolism, and the COCP is recommended as UKMEC 2 for women with a BMI of 30-34 kg/m² and UKMEC 3 for those with a BMI of 35 kg/m² or more. The COCP is contraindicated for women with a history of migraine with aura, but is UKMEC 3 for those with migraines without aura and UKMEC 2 for initiation. For women with epilepsy, consistent use of condoms is recommended in addition to other forms of contraception. The choice of contraceptive for women taking anti-epileptic medication depends on the specific medication, with the COCP and POP being UKMEC 3 for most medications, while the implant is UKMEC 2 and the Depo-Provera, IUD, and IUS are UKMEC 1. Lamotrigine has different recommendations, with the COCP being UKMEC 3 and the POP, implant, Depo-Provera, IUD, and IUS being UKMEC 1.

According to NICE guidelines for cervical cancer screening, if a person’s first repeat smear at 12 months is still positive for high-risk human papillomavirus (hrHPV), they should have another smear test 12 months later (i.e. at 24 months after the initial test). If the person remains hrHPV positive but has negative cytology results at 12 and 24 months, they should be referred to colposcopy. However, if they become hrHPV negative at 24 months, they can return to routine recall.

Understanding Cervical Cancer Screening Results

The cervical cancer screening program has evolved significantly in recent years, with the introduction of HPV testing allowing for further risk stratification. The NHS now uses an HPV first system, where a sample is tested for high-risk strains of human papillomavirus (hrHPV) first, and cytological examination is only performed if this is positive.

If the hrHPV test is negative, individuals can return to normal recall, unless they fall under the test of cure pathway, untreated CIN1 pathway, or require follow-up for incompletely excised cervical glandular intraepithelial neoplasia (CGIN) / stratified mucin producing intraepithelial lesion (SMILE) or cervical cancer. If the hrHPV test is positive, samples are examined cytologically, and if the cytology is abnormal, individuals will require colposcopy.

If the cytology is normal but the hrHPV test is positive, the test is repeated at 12 months. If the repeat test is still hrHPV positive and cytology is normal, a further repeat test is done 12 months later. If the hrHPV test is negative at 24 months, individuals can return to normal recall, but if it is still positive, they will require colposcopy. If the sample is inadequate, it will need to be repeated within 3 months, and if two consecutive samples are inadequate, colposcopy will be required.

For individuals who have previously had CIN, they should be invited for a test of cure repeat cervical sample in the community 6 months after treatment. The most common treatment for cervical intraepithelial neoplasia is large loop excision of transformation zone (LLETZ), which may be done during the initial colposcopy visit or at a later date depending on the individual clinic. Cryotherapy is an alternative technique.

Guidelines for Referral of Suspected Breast Cancer

Current NICE guidelines focus on symptoms and signs of breast cancer in individuals aged 30 and over. Referral for an appointment within two weeks is recommended for those with an unexplained breast lump with or without pain, or for those aged 50 and over with nipple discharge, retraction, or other changes of concern. Non-urgent referral may be considered for those under 30 with an unexplained breast lump. However, in cases where the cause of the problem may be an ill-fitting bra, conservative management is recommended. Topical NSAIDs may be given for symptom relief, but evening primrose oil has no evidence to support its use for cyclical mastalgia. Re-examination should be considered if symptoms persist.

The Kyleena® is a newly licensed levonorgestrel (LNG) intrauterine system (IUS) that is designed for contraceptive use for up to 5 years. Unlike the Mirena® IUS, it is not approved for managing heavy menstrual bleeding or providing endometrial protection as part of hormonal replacement therapy. The Kyleena® IUS is smaller in size than the Mirena® coil and contains 19.5mg of LNG, which is less than the 52mg found in the Mirena®. The Jaydess IUS contains the least amount of LNG at 13.5mg, but it is only licensed for 3 years. The Kyleena® releases a lower amount of systemic LNG than the Mirena® IUS, which may result in lower rates of amenorrhea and a higher number of bleeding or spotting days.

New intrauterine contraceptive devices include the Jaydess® IUS and Kyleena® IUS. The Jaydess® IUS is licensed for 3 years and has a smaller frame, narrower inserter tube, and less levonorgestrel than the Mirena® coil. The Kyleena® IUS has 19.5mg LNG, is smaller than the Mirena®, and is licensed for 5 years. Both result in lower serum levels of LNG, but the rate of amenorrhoea is less with Kyleena® compared to Mirena®.

To ensure reliable contraception, it is recommended to take a two-month course of Cerazette (desogestrel) as Nexplanon may not be dependable.

Implanon and Nexplanon are both subdermal contraceptive implants that slowly release the hormone etonogestrel to prevent ovulation and thicken cervical mucous. Nexplanon is an updated version of Implanon with a redesigned applicator to prevent deep insertions and is radiopaque for easier location. It is highly effective with a failure rate of 0.07/100 women-years and lasts for 3 years. It doesn’t contain estrogen, making it suitable for women with a history of thromboembolism or migraines. It can be inserted immediately after a termination of pregnancy. However, a trained professional is needed for insertion and removal, and additional contraception is required for the first 7 days if not inserted on days 1-5 of the menstrual cycle.

The main disadvantage of these implants is irregular and heavy bleeding, which can be managed with a co-prescription of the combined oral contraceptive pill. Other adverse effects include headache, nausea, and breast pain. Enzyme-inducing drugs may reduce the efficacy of Nexplanon, and women should switch to a different method or use additional contraception until 28 days after stopping the treatment. Contraindications include ischaemic heart disease/stroke, unexplained vaginal bleeding, past breast cancer, severe liver cirrhosis, and liver cancer. Breast cancer is a UKMEC 4 condition, meaning it represents an unacceptable risk if the contraceptive method is used.

If a patient experiences reddening and thickening of the nipple and areola, it is important to consider the possibility of Paget’s disease of the breast. However, it is also possible that the symptoms are caused by nipple eczema, especially if the patient has a history of atopy and no personal or family history of breast disease. It is important to rule out Paget’s disease, as it typically presents unilaterally and may be accompanied by bloody nipple discharge and an underlying breast lump.

Understanding Paget’s Disease of the Nipple

Paget’s disease of the nipple is a condition that affects the nipple and is associated with an underlying breast cancer. It is present in only 1-2% of patients with breast cancer, but it is important to note that half of these patients have an underlying mass lesion, and 90% of them will have an invasive carcinoma. Even patients without a mass lesion may still have an underlying carcinoma, which is found in 30% of cases. The remaining patients will have carcinoma in situ.

Unlike eczema of the nipple, Paget’s disease primarily affects the nipple and later spreads to the areolar. Diagnosis is made through a combination of punch biopsy, mammography, and ultrasound of the breast. Treatment options will depend on the underlying lesion.

HPV Testing in Cervical Screening

The use of HPV testing in cervical screening has been studied to determine if it can improve the accuracy of identifying women who need further investigation and treatment. Currently, only a small percentage of women referred for colposcopy actually require treatment as low-grade abnormalities often resolve on their own. By incorporating HPV testing, women with borderline or mild dyskaryosis who test negative for high-risk HPV can simply return to routine screening recall, while those who test positive are referred for colposcopy.

HPV testing is also used as a test of cure for women who have been treated for cervical intraepithelial neoplasia. Those with normal, borderline, or mild dyskaryosis smear results who are HPV negative can return to three-yearly recall. This approach ensures that women receive appropriate follow-up care while minimizing unnecessary referrals and treatments. Overall, the use of HPV testing in cervical screening has the potential to improve the accuracy and efficiency of the screening process.

Copper IUD as Emergency Contraception in the UK

A copper-containing intrauterine device (IUD) can be used as emergency contraception in the UK. It can be inserted within 120 hours (five days) of the first episode of unprotected sexual intercourse or up to five days after the earliest expected date of ovulation, regardless of the number of episodes or time since unprotected sex. A negative pregnancy test is not required before insertion of the copper IUD as emergency contraception.

It is important to note that the copper IUD should not be used from 48 hours to four weeks postpartum, as it falls under the UK medical eligibility criteria category 3. This means that it is advised not to be used during this time. Additionally, there is no need for the patient to have taken the progesterone emergency contraception pill beforehand as they will be using the copper device as their emergency contraception. Overall, the copper IUD is a safe and effective option for emergency contraception in the UK.

Partner notification is not necessary for bacterial vaginosis as it is not considered a sexually transmitted infection.

Bacterial vaginosis (BV) is a condition where there is an overgrowth of anaerobic organisms, particularly Gardnerella vaginalis, in the vagina. This leads to a decrease in the amount of lactobacilli, which produce lactic acid, resulting in an increase in vaginal pH. BV is not a sexually transmitted infection, but it is commonly seen in sexually active women. Symptoms include a fishy-smelling vaginal discharge, although some women may not experience any symptoms at all. Diagnosis is made using Amsel’s criteria, which includes the presence of thin, white discharge, clue cells on microscopy, a vaginal pH greater than 4.5, and a positive whiff test. Treatment involves oral metronidazole for 5-7 days, with a cure rate of 70-80%. However, relapse rates are high, with over 50% of women experiencing a recurrence within 3 months. Topical metronidazole or clindamycin may be used as alternatives.

Bacterial vaginosis during pregnancy can increase the risk of preterm labor, low birth weight, chorioamnionitis, and late miscarriage. It was previously recommended to avoid oral metronidazole in the first trimester and use topical clindamycin instead. However, recent guidelines suggest that oral metronidazole can be used throughout pregnancy. The British National Formulary (BNF) still advises against using high-dose metronidazole regimens. Clue cells, which are vaginal epithelial cells covered with bacteria, can be seen on microscopy in women with BV.

In cases of recurrent vaginal candidiasis, it is important to consider a blood test to rule out diabetes as a potential underlying cause. This is because poorly controlled diabetes can increase the risk of Candida growth. While it is important to treat the symptoms of the infection, it is also crucial to investigate any predisposing factors that may be contributing to the recurrence.

Measuring TSH, free T3 and T4 levels to rule out hyperthyroidism is not necessary as there is no link between an overactive thyroid and Candida infections. Similarly, mid-stream urine to rule out UTI is not necessary unless the patient’s symptoms suggest a urinary tract infection. Referral to a specialist is also not necessary as recurrent vaginal candidiasis can be managed in primary care with an induction-maintenance regimen of antifungals. Specialist referral may only be necessary if the infective organism is resistant to treatment or if it is a non-albicans Candida species.

Vaginal candidiasis, commonly known as ‘thrush’, is a prevalent condition that many women self-diagnose and treat. Candida albicans is responsible for 80% of cases, while other candida species cause the remaining 20%. Although most women have no predisposing factors, certain conditions such as diabetes mellitus, drug use (antibiotics, steroids), pregnancy, and immunosuppression (HIV) may increase the likelihood of developing vaginal candidiasis. Symptoms include non-offensive discharge resembling cottage cheese, vulvitis, dyspareunia, dysuria, itching, vulval erythema, fissuring, and satellite lesions.

Routine high vaginal swabs are not necessary if the clinical features are consistent with candidiasis. Treatment options include local or oral therapy. The NICE Clinical Knowledge Summaries recommends oral fluconazole 150 mg as a single dose as the first-line treatment. If oral therapy is contraindicated, a single dose of clotrimazole 500 mg intravaginal pessary may be used. If vulval symptoms are present, a topical imidazole may be added to an oral or intravaginal antifungal. Pregnant women should only use local treatments such as cream or pessaries, as oral treatments are not recommended.

Recurrent vaginal candidiasis is defined as four or more episodes per year by BASHH. Compliance with previous treatment should be checked, and the diagnosis of candidiasis should be confirmed. A high vaginal swab for microscopy and culture may be necessary, and a blood glucose test should be performed to exclude diabetes. Differential diagnoses such as lichen sclerosus should also be ruled out. An induction-maintenance regime may be used, consisting of oral fluconazole every three days for three doses as induction, followed by oral fluconazole weekly for six months as maintenance.

All sexually active individuals with a uterus, including transgender patients, should be offered cervical screening. This patient, who is sexually active and has an intact uterus, requires regular cervical smear tests regardless of their menstrual cycle or symptoms of abnormal vaginal bleeding. Testosterone therapy may affect the patient’s gender characteristics, but gender reassignment allows for legal recognition of their gender identity and rights, such as obtaining a new birth certificate, driving license, passport, and the ability to marry in their new gender. However, neither of these factors exempts the patient from cervical screening.

Contraceptive and Sexual Health Guidance for Transgender and Non-Binary Individuals

The Faculty of Sexual & Reproductive Healthcare has released guidance on contraceptive choices and sexual health for transgender and non-binary individuals. The guidance emphasizes the importance of sensitive communication and offering options that consider personal preferences, co-morbidities, and current medications or therapies. For those engaging in vaginal sex, condoms and dental dams are recommended to prevent sexually transmitted infections. Cervical screening and HPV vaccinations should also be offered. Those at risk of HIV transmission should be advised of pre-exposure prophylaxis and post-exposure prophylaxis.

For individuals assigned female at birth with a uterus, testosterone therapy doesn’t provide protection against pregnancy, and oestrogen-containing regimens are not recommended as they can antagonize the effect of testosterone therapy. Progesterone-only contraceptives are considered safe, and non-hormonal intrauterine devices may also suspend menstruation. Emergency contraception may be required following unprotected vaginal intercourse, and either oral formulation or the non-hormonal intrauterine device may be considered.

In patients assigned male at birth, hormone therapy may reduce or cease sperm production, but the variability of its effects means it cannot be relied upon as a method of contraception. Condoms are recommended for those engaging in vaginal sex to avoid the risk of pregnancy. The guidance stresses the importance of offering individuals options that take into account their personal circumstances and preferences.

The NHS is extending its breast screening initiative to cover women between the ages of 47 and 73. Women over this age can still undergo screening by making their own arrangements.

Breast Cancer Screening and Familial Risk Factors

Breast cancer screening is offered to women aged 50-70 years through the NHS Breast Screening Programme, with mammograms offered every three years. While the effectiveness of breast screening is debated, it is estimated that the programme saves around 1,400 lives annually. Women over 70 years may still have mammograms but are encouraged to make their own appointments.

For those with familial risk factors, NICE guidelines recommend referral to a breast clinic for further assessment. Those with one first-degree or second-degree relative diagnosed with breast cancer do not need referral unless certain factors are present in the family history, such as early age of diagnosis, bilateral breast cancer, male breast cancer, ovarian cancer, Jewish ancestry, or complicated patterns of multiple cancers at a young age. Women with an increased risk of breast cancer due to family history may be offered screening from a younger age.

The appropriate technique to treat cervical intraepithelial neoplasia (CIN2 or CIN3) is urgent large loop excision of the transformation zone (LLETZ). This procedure is commonly performed in the same appointment or in a prompt subsequent appointment. Cryotherapy may also be an option to remove the abnormal cells. Offering the HPV vaccination is not a correct answer as it is only offered to girls and boys aged 12 to 13. A repeat cervical smear within 3 months is also not a correct answer, as it is only offered if the high-risk human papillomavirus (hrHPV) test result is unavailable or cytology is inadequate. Routine referral to gynaecology is also not indicated, as the patient would already be followed up by the colposcopy service.

Understanding Cervical Cancer Screening Results

The cervical cancer screening program has evolved significantly in recent years, with the introduction of HPV testing allowing for further risk stratification. The NHS now uses an HPV first system, where a sample is tested for high-risk strains of human papillomavirus (hrHPV) first, and cytological examination is only performed if this is positive.

If the hrHPV test is negative, individuals can return to normal recall, unless they fall under the test of cure pathway, untreated CIN1 pathway, or require follow-up for incompletely excised cervical glandular intraepithelial neoplasia (CGIN) / stratified mucin producing intraepithelial lesion (SMILE) or cervical cancer. If the hrHPV test is positive, samples are examined cytologically, and if the cytology is abnormal, individuals will require colposcopy.

If the cytology is normal but the hrHPV test is positive, the test is repeated at 12 months. If the repeat test is still hrHPV positive and cytology is normal, a further repeat test is done 12 months later. If the hrHPV test is negative at 24 months, individuals can return to normal recall, but if it is still positive, they will require colposcopy. If the sample is inadequate, it will need to be repeated within 3 months, and if two consecutive samples are inadequate, colposcopy will be required.

For individuals who have previously had CIN, they should be invited for a test of cure repeat cervical sample in the community 6 months after treatment. The most common treatment for cervical intraepithelial neoplasia is large loop excision of transformation zone (LLETZ), which may be done during the initial colposcopy visit or at a later date depending on the individual clinic. Cryotherapy is an alternative technique.

If simple analgesia with paracetamol and NSAIDs is not effective in treating endometriosis symptoms, hormonal treatment with the combined oral contraceptive pill or a progestogen should be considered.

Although a referral to gynaecology may be necessary due to the recurrence of symptoms and potential pelvic/bowel involvement, primary care can offer further treatment options in the meantime. Hormonal treatment is recommended for this patient, and the combined oral contraceptive pill or any progestogen options can be considered. As the patient plans to start a family soon, a hormonal option that can be quickly reversed is preferred.

Buscopan is not an appropriate treatment for endometriosis. While it may provide some relief for pelvic symptoms during menstruation, it is not a treatment for the condition. It may be used to alleviate cramps associated with irritable bowel syndrome.

Injectable depo-provera is not the best option for this patient as it may delay the return of fertility, which conflicts with her desire to start a family soon.

Opioid analgesia is not recommended for endometriosis treatment as it carries the risk of side effects and dependence. It is not a suitable long-term solution for managing symptoms.

Endometriosis is a condition where endometrial tissue grows outside of the uterus, affecting around 10% of women of reproductive age. Symptoms include chronic pelvic pain, painful periods, pain during sex, and subfertility. Diagnosis is made through laparoscopy, and treatment depends on the severity of symptoms. First-line treatments include NSAIDs and hormonal treatments such as the combined oral contraceptive pill or progestogens. If these do not improve symptoms or fertility is a priority, referral to secondary care may be necessary. Treatment options in secondary care include GnRH analogues and surgery, with laparoscopic excision or ablation of endometriosis plus adhesiolysis recommended for women trying to conceive. Ovarian cystectomy may also be necessary for endometriomas.

It is incorrect to advise the patient that she doesn’t require emergency contraception as she is at risk of pregnancy. Although oral emergency contraception may not be effective if taken after ovulation, the patient’s last menstrual period was only 10 days ago, making it a potential option. The patient has declined an intrauterine device, which is the most effective option, but should not be pressured into using it for emergency contraception. Ulipristal acetate is not recommended for the patient due to her severe asthma and use of oral steroids. It is important to note that patients with a BMI over 26 or weight over 70 kg should be given a double dose of levonorgestrel for emergency contraception. Additionally, it is crucial to discuss ongoing contraception and sexual health with the patient.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, and should be taken as soon as possible after unprotected sexual intercourse (UPSI) for maximum efficacy. The single dose of levonorgestrel is 1.5mg, but should be doubled for those with a BMI over 26 or weight over 70kg. It is safe and well-tolerated, but may cause vomiting in around 1% of women. Ulipristal, on the other hand, is a selective progesterone receptor modulator that inhibits ovulation. It should be taken within 120 hours after intercourse, and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which may inhibit fertilization or implantation. It must be inserted within 5 days of UPSI, or up to 5 days after the likely ovulation date. Prophylactic antibiotics may be given if the patient is at high-risk of sexually transmitted infection. The IUD is 99% effective regardless of where it is used in the cycle, and may be left in-situ for long-term contraception.

If you experience ovarian hyperstimulation syndrome, your chances of developing ovarian torsion are higher. This is because the ovary becomes enlarged, which increases the risk of torsion. If you experience sudden pelvic pain and vomiting on one side, it may be a sign of ovarian torsion.

While an ovarian cyst can cause pelvic pain, the sudden onset of pain suggests a cyst accident, such as rupture, haemorrhage, or torsion.

Pelvic inflammatory disease typically causes pelvic pain, fever, and abnormal vaginal bleeding.

Appendicitis usually causes pain in the right iliac fossa.

Understanding Ovarian Torsion

Ovarian torsion is a condition where the ovary twists on its supporting ligaments, leading to a compromised blood supply. This can result in partial or complete torsion of the ovary. When the fallopian tube is also affected, it is referred to as adnexal torsion. The condition is commonly associated with ovarian masses, pregnancy, and ovarian hyperstimulation syndrome. Women of reproductive age are also at risk of developing ovarian torsion.

The most common symptom of ovarian torsion is sudden, severe abdominal pain that is often colicky in nature. Other symptoms include vomiting, distress, and in some cases, fever. Adnexal tenderness may be detected during a vaginal examination. Ultrasound may reveal free fluid or a whirlpool sign. Laparoscopy is usually both diagnostic and therapeutic for ovarian torsion.

Women and men who are taking leflunomide must use effective contraception for a minimum of 2 years and 3 months respectively after discontinuing the medication, similar to the requirements for thalidomide.

Leflunomide: A DMARD for Rheumatoid Arthritis

Leflunomide is a type of disease modifying anti-rheumatic drug (DMARD) that is commonly used to manage rheumatoid arthritis. It is important to note that this medication has a very long half-life, which means that its teratogenic potential should be taken into consideration. As such, it is contraindicated in pregnant women, and effective contraception is essential during treatment and for at least two years after treatment in women, and at least three months after treatment in men. Caution should also be exercised in patients with pre-existing lung and liver disease.

Like any medication, leflunomide can cause adverse effects. Some of the most common side effects include gastrointestinal issues such as diarrhea, hypertension, weight loss or anorexia, peripheral neuropathy, myelosuppression, and pneumonitis. To monitor for any potential complications, patients taking leflunomide should have their full blood count (FBC), liver function tests (LFT), and blood pressure checked regularly.

If a patient needs to stop taking leflunomide, it is important to note that the medication has a very long wash-out period of up to a year. To help speed up the process, co-administration of cholestyramine may be necessary. Overall, leflunomide can be an effective treatment option for rheumatoid arthritis, but it is important to carefully consider its potential risks and benefits before starting treatment.

Prior to initiating tamoxifen treatment, women should be informed about the elevated risk of VTE, which is one of the most significant side effects of the medication. Additionally, tamoxifen has been linked to an increased risk of endometrial cancer.

Risk Factors for Venous Thromboembolism

Venous thromboembolism (VTE) is a condition where blood clots form in the veins, which can lead to serious complications such as pulmonary embolism (PE). While some common predisposing factors include malignancy, pregnancy, and the period following an operation, there are many other factors that can increase the risk of VTE. These include underlying conditions such as heart failure, thrombophilia, and nephrotic syndrome, as well as medication use such as the combined oral contraceptive pill and antipsychotics. It is important to note that around 40% of patients diagnosed with a PE have no major risk factors. Therefore, it is crucial to be aware of all potential risk factors and take appropriate measures to prevent VTE.

Norethisterone taken orally is a viable solution for quickly halting heavy menstrual bleeding on a temporary basis.

Managing Heavy Menstrual Bleeding

Heavy menstrual bleeding, also known as menorrhagia, is a condition where a woman experiences excessive blood loss during her menstrual cycle. While it was previously defined as total blood loss of more than 80 ml per cycle, the management of menorrhagia now depends on the woman’s perception of what is excessive. Prior to the 1990s, hysterectomy was a common treatment for heavy periods, but the approach has since shifted.

To manage menorrhagia, a full blood count should be performed in all women, and a routine transvaginal ultrasound scan should be arranged if symptoms suggest a structural or histological abnormality. If contraception is not required, mefenamic acid or tranexamic acid can be used. If there is no improvement, other drugs can be tried while awaiting referral.

For women who require contraception, options include the intrauterine system (Mirena), combined oral contraceptive pill, and long-acting progestogens. Norethisterone can also be used as a short-term option to rapidly stop heavy menstrual bleeding. A flowchart can be used to guide the management of menorrhagia.

Contraception Options for Patients with Past Breast Cancer

Patients with a past history of breast cancer should be advised to use barrier contraception or the intrauterine device (IUD) only. Hormonal containing contraception, including progestogens, are UKMEC 3 in these patients. This means that the benefits of using hormonal contraception may outweigh the risks, but caution should be taken and alternative options should be considered.

The IUD and implant are also UKMEC 3 in patients with past breast cancer, while the IUD and progesterone-only pill are also considered UKMEC 3. It is important for patients to discuss their options with their healthcare provider and weigh the potential benefits and risks of each method before making a decision. By considering all options and taking precautions, patients with past breast cancer can still have access to effective contraception while minimizing potential risks.